Identification of the binding sites and selectivity of sarpogrelate, a novel 5-HT2 antagonist, to human 5-HT2A, 5-HT2B and 5-HT2C receptor subtypes by molecular modeling

Life Sciences

Volumn 73, Issue 2, 2003, Pages 193-207

  Rashid, Mamunur ^a   Manivet, Philippe ^b,c   Nishio, Hiroaki ^d   Pratuangdejkul, Jaturong ^b,c   Rajab, Mazen ^b,c   Ishiguro, Masaji ^e   Launay, Jean Marie ^b,c   Nagatomo, Takafumi ^a  

^a NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

^b HÔPITAL LARIBOISIÈRE   (France)

^c UFR des Sci Pharmaceut/Biologiques ^*  (France)

^d FUKUYAMA UNIVERSITY   (Japan)

^e SUNTORY INSTITUTE FOR BIOORGANIC RESEARCH   (Japan)

Author keywords

5 HT2 receptor family; Antagonist; Molecular modeling; Sarpogrelate; Selectivity

Indexed keywords

ALANINE; ASPARTIC ACID; ISOLEUCINE; PHENYLALANINE; PROLINE; RHODOPSIN; SARPOGRELATE; SERINE; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 2C RECEPTOR; TRYPTOPHAN; VALINE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING SITE; CELL MEMBRANE; CHO CELL; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; GENETIC TRANSFECTION; MOLECULAR MODEL; NONHUMAN; STEREOCHEMISTRY;

EID: 0038401338     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(03)00227-3     Document Type: Article

References (40)

1. Baldwin J.M. Structure and function of receptors coupled to G proteins. Current Opinion in Cell Biology. 6:1994;180-190.
2. Ballesteros J.A., Weinstein H. Integrated methods for the construction of three dimensional models and computational probing of structure-function relations in G-protein coupled receptors. Methods in Neurosciences. 25:1995;366-428.
3. 2 receptor subtypes: a family re-united? Trends in Pharmacological Sciences. 16:1995;105-110.
4. 2C receptors. British Journal of Pharmacology. 115:1995;622-628.
5. Bradford M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry. 72:1976;23422-23426.
6. Brea J., Rodrigo J., Carrieri A., Sanz F., Cadavid M.I., Enguix M.J., Villazón M., Mengod G., Caro Y., Masaguer C.F., Ravina E., Centeno N.B., Carotti A., Loza M.I. New serotonin 5-HT(2A), 5-HT(2B), and 5-HT(2C) receptor antagonists: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo and heterocycloalkanones. Journal of Medicinal Chemistry. 45:2002;54-61.
7. Brooks B.R., Bruccoleri R.E., Olafson B.D., States D.J., Swaminathan S., Karplus M. CHARMM a program for macromolecular energy, minimization and dynamics calculations. Journal of Computational Chemistry. 4:1983;187-212.
8. Burns C.M., Chu H., Reuter S.M., Hutchinson L.K., Canton H., Sanders-Bush E., Emeson R.B. Regulation of serotonin-2C receptor G-protein coupling by RNA editing. Nature. 387:1997;303-308.
9. 50) of an enzymatic reaction. Biochemical Pharmacology. 22:1973;3099-3108.
10. Choudhary M.S., Sachs N., Uluer A., Glennon A., Westkaemper R.B., Roth B.L. Differential ergoline and ergopeptine binding to 5-hydroxytryptamine2A receptors: ergolines require an aromatic residue at position 340 for high affinity binding. Molecular Pharmacology. 47:1995;450-457.
11. Donnelly D., Findlay J.B.C., Blundell T.L. The evolution and structure of aminergic G-protein-coupled receptors. Receptors Channels. 2:1994;61-68.
12. 2 antagonist, sarpogrelate hydrochloride, shows inbibitory effects on both contraction and relaxation mediated by 5-HT receptor subtypes in porcine coronary arteries. Pharmacology. 61:2000;263-268.
13. Hara H., Kitajima A., Shimada H., Tamao Y. Antithrombic effect of MCI-9042, a new antiplatelet agent on experimental thrombosis models. Thrombosis and Haemostasis. 66:1991;484-488.
14. 2-serotonergic receptor antagonist. Thrombosis and Haemostosis. 65:1991;415-420.
15. Hibert M., Trumpp-Kallmeyer S., Bruinvels A., Hoflack J. Three-dimensional models of neurotransmitter G-binding protein-coupled receptors. Molecular Pharmacology. 40:1991;8-15.
16. Hoyer D., Hannon J.P., Martin G.R. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacology Biochemistry and Behavior. 71(4):2000;533-554.
17. Ito K., Notsu T. Effect of sarpogrelate hydrochloride (MCI-9042) on peripheral circulation of chronic arterial occlusive diseases. Journal of Clinical and Therapeutical Medicine. 7:1991;1243-1251.
18. 2C receptor interactions. European Journal of Pharmacology. 306:1996;195-210.
19. 2B receptors: molecular modeling and site-directed mutagenesis. Journal of Biological Chemistry. 277(19):2002;17170-17178.
20. Maruyama K., Kinami J., Sugita Y., Takada Y., Sugiyama E., Tsuchihashi H., Nagatomo T. MCI-9042: high affinity for serotonergic receptors as assessed by radioligand binding assay. Journal of Pharmacobio-Dynamics. 14:1991;177-181.
21. 2A serotonergic receptor antagonist, inhibits serotonin-induced coronary artery spasm in a porcine model. Journal of Cardiovascular Pharmacology. 35:2000;294-301.
22. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., Olson A.J. Automated docking using a lamarckian genetic algorithm and and empirical binding free energy function. Journal of Computational Chemistry. 19:1998;1639-1662.
23. Nakamura K., Kariyazono H., Moriyama Y., Toyohira H., Kubo H., Yotsumoto G., Taira A., Yamada K. Effects of sarpogrelate hydrochloride on platelet aggregation, and its relation to the release of serotonin and P-selectin. Blood Coagulation and Fibrinolysis. 10:1999;513-519.
24. Nishio H., Inoue A., Nakata Y. Binding affinity of sarpogrelate, a new antiplatelet agent, and its metabolite for serotonin receptor subtypes. Archives Internationales de Pharmacodynamie et de therapie. 331:1996;189-202.
25. Oliveira L., Paiva A.C.M., Vriend G.J. A low resolution model for the interaction of G proteins with G protein-coupled receptors. Protein Engineering. 12(12):1999;1087-1095.
26. 2A receptor specificity, stereoselectivity and modulation of ritanserin-induced depression of 5-HT contractions in rat tail artery. Journal of Pharmacy and Pharmacology. 47:1995;310-316.
27. Ravina E., Negreira J., Cid J., Masaguer C.F., Rosa E., Rivas M.E., Fontenla J.A., Loza M.I., Tristan H., Cadavid M.I., Sanz F., Lozoya E., Carotti A., Carrieri A. Conformationally constrained butyrophenones with mixed dopaminergic (D(2)) and serotoninergic (5-HT(2A), 5-HT(2C)) affinities: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo- and -thienocycloalkanones as putative atypical antipsychotics. Journal of Medicinal Chemistry. 42(15):1999;2774-2797.
28. Roth B.L., Shoham M., Choudhary M.S., Khan N. Identification of conserved aromatic residues essential for agonist binding and second messenger production at 5-hydroxytryptamine2A receptors. Molecular Pharmacology. 52:1997;259-267.
29. Roth B.L., Willins D.L., Kristiansen K., Kroeze W.K. 5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets function. Pharmacology and Therapeutics. 79:1998;231-257.
30. Sharma S.K., Zahradka P., Chapman D., Kumamoto H., Takeda N., Dhalla N.S. Inhibition of serotonin-induced vascular smooth muscle cell proliferation by sarpogrelate. Journal of Pharmacology and Experimental Therapeutics. 290:1999;1475-1481.
31. Teller D.C., Okada T., Behnke C.A., Palczewski K., Stenkamp R.E. Advances in determination of a high-resolution three-dimensional structure of rhodopsin, a model of G-protein-coupled receptors (GPCRs). Biochemistry. 40(26):2001;7761-7772.
32. Thompson J.D., Plewniak F., Poch O. A comprehensive comparison of multiple sequence alignment programs. Nucleic Acids Research. 27:1999;2682-2690.
33. Trumpp-Kallmeyer S., Hoflack J., Bruinvels A., Hibert M. Modeling of G-protein-coupled receptors: application to dopamine, adrenaline, serotonin, acetylcholine, and mammalian opsin receptors. Journal of Medicinal Chemistry. 35:1992;3448-3462.
34. Visiers I., Ballesteros J.A., Weinstein H. Three-dimensional representations of G protein-coupled receptor structures and mechanisms. Methods in Enzymology. 343:2002;329-371.
35. Wallace A.C., Laskowski R.A., Thornton J.M. A program to generate schematic diagrams of protein-ligand interactions. Protein Engineering. 8:1995;127-134.
36. Wang C.D., Gallaher T.K., Shih J.C. Site-directed mutagenesis of the serotonin 5-hydroxytrypamine2 receptor: identification of amino acids necessary for ligand binding and receptor activation. Molecular Pharmacology. 43:1993;931-940.
37. Westkaemper R.B., Glennon R.A. Approaches to molecular modeling studies and specific application to serotonin ligands and receptors. Pharmacology Biochemistry and Behavior. 40(4):1991;1019-1031.
38. 2C receptors. Medicinal Chemistry Research. 3:1993;317-334.
39. 2 receptor antagonist, sarpogrelate, on thrombolysis with modified tissue plasminogen activator in different laser-induced thrombosis models. Haemostasis. 30:2000;321-332.
40. Zhang D., Weinstein H. Polarity conserved positions in transmembrane domains of G-protein coupled receptors and bacteriorhodopsin. FEBS Letters. 337:1994;207-212.